In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese herbal recall

This article was originally published in The Tan Sheet

Executive Summary

New York City-based Kingsway Trading Inc. is voluntarily recalling two of its Chinese herbal supplements because they contain aristolochic acid; the ingredient was found in Kingsway Trading's Expellin Extract and Cardioflex. Aristolochic acid has been linked to an increased risk of kidney cancer and in some cases kidney failure (1"The Tan Sheet" April 16, 2001, p. 9). An FDA district office in New York collected samples during a routine inspection and subsequent testing revealed the presence of the ingredient. The company issued a recall letter to customers Nov. 12...

You may also be interested in...



Aristolochia Renal Disease Link Reported In Two U.S. Cases

Aristolochic acid-containing botanicals were used by two individuals in the U.S. who developed end-stage renal disease, FDA reports in an April 4 letter urging health professionals to more closely monitor their patients' dietary supplement intake.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS097511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel